This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cigna (CI) Divests to Deepen Focus on Healthcare, Repay Debt
by Zacks Equity Research
Cigna's (CI) sale of its non-health unit paves way for it to focus on its core business and make debt repayments.
Top Research Reports for PayPal, Shopify & BP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PayPal Holdings (PYPL), Shopify (SHOP) and BP p.l.c. (BP).
Teladoc (TDOC) Up 130% YTD: Will the Rally Continue in 2021?
by Zacks Equity Research
Buoyancy in demand for telehealth consultation services along with a sturdy inorganic growth story will continue to push Teladoc's (TDOC) stock higher in 2021.
Here's Why You Should Hold Cigna (CI) Stock in Your Portfolio
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of a strong Medicare business and adequate cash generation capabilities.
Cigna (CI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cigna (CI) closed the most recent trading day at $209.35, moving -1.55% from the previous trading session.
Humana (HUM) Boosts Value-Based Care With New PCF Model
by Zacks Equity Research
Humana (HUM) enhances its value-based healthcare model to ease the financial pressure on members and add to its capabilities.
Humana (HUM) Ties Up to Boost Presence Across West Virginia
by Zacks Equity Research
Humana (HUM) partners with St. Mary's Medical Center, which intends to offer improved health outcomes across West Virginia.
Why Is Cigna (CI) Up 1.6% Since Last Earnings Report?
by Zacks Equity Research
Cigna (CI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Humana (HUM), St. Luke's Health Tie Up for Enhanced Healthcare
by Zacks Equity Research
Humana (HUM) teams up with St. Luke's Health Partners to provide better medical care in Idaho.
Cigna (CI) Expands Presence on Exchanges in North Carolina (Revised)
by Zacks Equity Research
Cigna (CI) expands ACA offering in additional counties across North Carolina with enhanced benefits.
Cigna (CI) Extends Medicare Advantage in North Carolina
by Sapna Bagaria
Cigna (CI) is providing Medicare Advantage business in 63 new counties within the state of North Carolina.
Humana (HUM) Enhances Value-Based Care With Vancouver Clinic
by Zacks Equity Research
Humana (HUM) intends to strengthen value-based relationship with Vancouver Clinic, which is likely to offer improved health outcomes across Clark County.
Humana (HUM) Joins Envision for Better Healthcare in Florida
by Zacks Equity Research
Humana (HUM) expands partnership with Envision Healthcare to provide in-network medical care to its commercial, Medicare and Medicaid members in Florida.
Cigna (CI) Rides on a Diversified Business, Capital Position
by Zacks Equity Research
Cigna's (CI) prolific business profile and a solid balance sheet position poise it well for long-term growth.
Cigna (CI) Q3 Earnings & Revenues Beat Estimates, Grow Y/Y
by Zacks Equity Research
Cigna's (CI) Q3 results reflect a strong fundamental performance across its businesses besides the return of medical utilization to more typical levels and COVID-19-related adversities.
Has Cigna (CI) Outpaced Other Finance Stocks This Year?
by Zacks Equity Research
Is (CI) Outperforming Other Finance Stocks This Year?
Cigna (CI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 3.76% and 4.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Cigna (CI) Maintain Its Beat Streak in Q3 Earnings?
by Zacks Equity Research
Cigna's (CI) Q3 results are likely to reflect revenue growth owing to a strong fundamental performance. Earnings, however, might have been affected by steep medical costs from moderation in deferment of care related to the COVID-19 pandemic.
Is a Surprise Coming for Cigna (CI) This Earnings Season?
by Zacks Equity Research
Cigna (CI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Berkshire Hathaway (BRK.B) in Q3 Earnings?
by Zacks Equity Research
Berkshire Hathaway (BRK.B) Q3 results will likely reflect higher catastrophe loss.
Are Investors Undervaluing Cigna (CI) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Forget Bargain Hunting: Play 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
6 Multiline Insurers to Watch Out for Amid Operational Challenges
by Tanuka De
Better pricing, product redesigns and increased adoption of technology are expected to aid multiline insurers like CI, MET, CNO, HMN, ORI, and MTG. However, a low-rate environment remains a headwind.
Cigna (CI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Cigna (CI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Growth Stocks to Buy for October 29th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, October 29th.